Immuron Ltd — Board/Management Information 2009

May 28, 2009

==> picture [193 x 41] intentionally omitted <==

29 May 2009

The Manager The Company Announcement Office Australian Stock Exchange Sydney NSW

Dear Sir

Immuron announces the following Management changes.

• The Company’s existing contracts with Dr Zeil Rosenberg (Chief Executive Officer) and Dr Oren Fuerst (VP Business Development) have not been renewed and will expire at the end of May 2009.

• Professor Colin Chapman will become Executive Chairman until a replacement Chief Executive Officer is appointed

• Mr Arie Nudel, a current Director, has been reappointed Manager Investor Relations

The Board will be undertaking an executive search to identify a new Chief Executive, and until that appointment there will be no changes planned to the Company’s present business programme. A review of the current programme and strategies will be one of the initial functions undertaken by the new Chief Executive Officer upon his/her appointment.

As previously announced on 20 March, the Company has entered into a conditional agreement to acquire the rights to patent technology from Hadasit Medical Research Services & Development Limited (Hadasit) to develop novel methods in the treatment of certain chronic diseases. Under the terms of that conditional agreement shareholder approval is required for the issue of shares to Hadasit which, post issue, will represent 19.99% of the total issued shares of Immuron Limited. This meeting will be held on 9 July and the notice of meeting and explanatory statement will be forwarded to shareholders within the next 2 weeks.

The Board is confident that the above management changes will have no impact on the proposed research to be conducted in Australia and Israel in respect of the technology acquired. The Chairman of Immuron Limited, Professor Colin Chapman, visited Hadassah Medical Centre earlier this month to cement the relationship with Professor Yaron Ilan and his team of scientists who will be conducting the research.

For further information please contact the Chairman, Professor Colin Chapman.

==> picture [108 x 64] intentionally omitted <==

Graeme Stevens Company Secretary Immuron Limited

ABN 80 063 114 045 Level 1, 39 Leveson Street North Melbourne VIC 3051 AUSTRALIA

Tel (61) 3 9018 4880 Fax (61) 3 9018 4881 www.immuron.com